5 days ago · Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February 2011. For information on our organization please visit the Janssen Infectious Diseases and Vaccines website. For information on Crucell vaccines and contact details, please see below

Janssen Vaccines, formerly Crucell, is a biotechnology company specializing in vaccines and biopharmaceutical technologies. It was formed when Johnson & Johnson acquired the Dutch biotech company Crucell.

Crucell, a biopharmaceutical company specializing in vaccines and antibodies to fight infectious disease worldwide, was acquired by Johnson & Johnson. The purchase equipped Johnson & Johnson with the tools to produce vaccines for the first time.

Crucell N.V. is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. Its vaccines are sold in public and private markets worldwide.

Mar 8, 2011 · Johnson & Johnson (J&J) has acquired Netherlands-based biopharmaceutical company Crucell for close to $2.4 billion dollars, moving J&J prominently into the arena of vaccine development, according to a company press release.

Crucell is a global biopharmaceutical company dedicated to bringing meaningful innovation to global health.

Jul 8, 2011 · Crucell is one of the major suppliers of vaccines to UNICEF and the developing world. Crucell was the first manufacturer to launch a fully-liquid pentavalent vaccine. Called Quinvaxem ® , this innovative combination vaccine protects against …

Jan 5, 2015 · Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases.

Aug 10, 2012 · Crucell is a biopharmaceutical company dedicated to bringing meaningful innovation to global health. Our teams focus on the discovery, development, manufacture and marketing of vaccines and antibodies to protect people worldwide from major health threats.

Summarized under the catch-phrase “huMADE,” Crucell focuses on the development of human antibody-based therapeutics for treatment of cancer and inflammatory diseases and for the production of human vaccines.